Loading data for SRPT — first visit, this takes a few seconds.

Sarepta Therapeutics, Inc. (SRPT)

NasdaqGS: SRPT · Real-Time Price · USD

20.96

+0.10 (0.48%)

At close: Aug 31, 2026, 7:06 PM

Alert

The price, the headline numbers and the latest news, in one place.

No data available

Bid	16.14
Market Cap	2.19B
Revenue (ttm)	1.97B
Net Income (ttm)	-137M
	0.20
	-1.57
	n/a
	8.07
P/B (ttm)	1.43
P/S (ttm)	1.11
Earnings Date	Nov 4, 2026

Ask	22.55
Volume	735,722
Avg. Volume (20D)	3,348,350
Open	20.56
Previous Close	20.86
Day's Range	20.18 - 21.16
52-Week Range	14.68 - 25.32
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About SRPT

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in ...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 4, 1997

Employees 835

Stock Exchange NasdaqGS

Ticker Symbol SRPT

Website https://www.sarepta.com

Full Company Profile

Financial Performance

In 2025, Sarepta Therapeutics's revenue was 2.2B, an increase of 15.58% compared to the previous year's 1.9B. Earnings were -713.41M, a decrease of -403.27%.

Financial Statements

Earnings Surprise

Sarepta Therapeutics has released their quarterly earnings on Aug 5, 2026:

Revenue of $401.25M misses estimates by $0, with -34.34% YoY decline.
EPS of 0.64 exceeds estimates by 0.15, with -68.32% YoY decline.

Next Earnings Release

Sarepta Therapeutics, Inc. is scheduled to release its earnings on Nov 4, 2026, during market hours.
Analysts project revenue of ... Upgrade

Why Price Moved

News

4 days ago · Stocktwits

SRPT On Track For Best Week In 5 Months Ahead Of Late-2026 Clinical Data — Retail Eyes ‘Monumental Comeback’

Investors are now awaiting extra data from Sarepta’s mid-stage studies in two muscle diseases, facioscapulohumeral muscular dystrophy and myotonic dystrophy.

5 days ago · Trefis

Moderna Stock Carries A Market Value Its Revenue Does Not Support

Moderna's commercial business has shrunk and is lossmaking, which puts the weight of its market value on a pipeline rather than on revenue.

6 days ago · Simply Wall St.

Sarepta (SRPT) Stock Looks Fully Valued As Sales Trail Fair Value

Sarepta Therapeutics stock has seen a steep share price decline over the past few years, yet on current market multiples it still screens as expensive rather than clearly cheap. With the valuation che...

1 week ago · Trefis

Moderna Stock Had A Readout Waiting In Plain Sight

Before the melanoma result, the visible signs were an enrolled trial, a partner paying half its cost, and a market that had stopped pricing an unusually large move.

1 week ago · Zacks

KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak

Keros gets a $20M Takeda milestone, boosting cash and flexibility, but weak revenue visibility keeps collaboration income in focus.

Page 1 of 2

Sarepta Therapeutics, Inc. (SRPT)